Hereditary Angioedema Research

Recent studies on hereditary angioedema (HAE) have focused on improving early diagnosis, treatment strategies, and understanding the genetic basis of the disease. Research from 2019 to 2024 has led to the development of novel therapies, including targeted biologics that inhibit the factors causing angioedema attacks. Clinical trials have shown that these new treatments, including C1-inhibitor replacement therapies and kallikrein inhibitors, significantly reduce the frequency and severity of attacks. The genetic insights gained from recent studies also aid in earlier diagnosis, allowing for more effective long-term management of the condition and better patient outcomes.

    Related Conference of Hereditary Angioedema Research

    February 24-25, 2025

    2nd International Conference on Pharmacognosy

    Madrid, Spain
    February 27-28, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    March 10-11, 2025

    35th Annual European Pharma Congress

    Rome, Italy
    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Aix-en-Provence, France
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Hereditary Angioedema Research Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in